Mithra Pharmaceuticals Strengthens Position In The Belgian Contraception Market
• Mithra builds on leading position in Belgian contraceptive market
• Mithra achieves significant increase in 2016 sales
• Market trend validates Mithra’s Estetrol-based programs
Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97%[1] to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.
The Belgian contraception market grew by 2.01 % during 2016 or 229.389 cycles. In 2016, there were 17.645 more women using a contraceptive product, of these Mithra has captured 16.659 of the new patients, representing 94.4% of the total growth of the market in 2016.
Mithra remains largely in pole position in terms of sold cycles with a significant growth of 4.23 % or +216.576 cyles. In 2016, over 410.500 women[2] (almost 1 in every 2 women who take an oral contraceptive) use a Mithra oral contraceptive product in Belgium.
François Fornieri, CEO of Mithra Pharmaceuticals: “This leading position strengthens the credibility of Mithra in its own market, but also internationally, which is positive for our Estetrol-based R&D project in contraception which presents a lower VTE risk and an improved safety profile over currently available products.”
• Mithra achieves significant increase in 2016 sales
• Market trend validates Mithra’s Estetrol-based programs
Liège, Belgium January 31, 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it increased its market share in Belgium by 0.97%[1] to 45.84% compared to 2015, placing it ahead of Bayer and Merck. The Company also achieved an increase in sales of 4.23%.
The Belgian contraception market grew by 2.01 % during 2016 or 229.389 cycles. In 2016, there were 17.645 more women using a contraceptive product, of these Mithra has captured 16.659 of the new patients, representing 94.4% of the total growth of the market in 2016.
Mithra remains largely in pole position in terms of sold cycles with a significant growth of 4.23 % or +216.576 cyles. In 2016, over 410.500 women[2] (almost 1 in every 2 women who take an oral contraceptive) use a Mithra oral contraceptive product in Belgium.
François Fornieri, CEO of Mithra Pharmaceuticals: “This leading position strengthens the credibility of Mithra in its own market, but also internationally, which is positive for our Estetrol-based R&D project in contraception which presents a lower VTE risk and an improved safety profile over currently available products.”